ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

This website is best viewed using the horizontal display on your tablet device.

This website is best viewed using the vertical display on your mobile device.

Survival at 24-month Follow-up Analysis1-3*




(95% CI, 6.08-12.22)

mPFS with sCR



(95% CI, 14.39-NE)




(95% CI, 18.96-NE)

OS was a secondary endpoint of KarMMa and was not statistically tested in the setting of a single-arm trial. OS data are not in the USPI and should be interpreted with caution in a single-arm trial. The statistical significance of OS is not known. Median follow-up of 19.9 months (range 0.2-31.5): 50 events and 50 deaths occurred prior to data cutoff December 2020.

Median OS by best response

Median OS by Best Response Graph
Median OS by Best Response Graph

Efficacy data based on long-term follow-up analysis (median time from ABECMA infusion to data cutoff 27.3 months [range 24.1 to 33.1]; N=100). Data were generally consistent with the primary analysis. See ORR at primary analysis.

mOS=median overall survival; mPFS=median progression-free survival; OS=overall survival; NE=not estimable; PR=partial response; sCR=stringent complete response; TTNT=time to next treatment; VGPR=very good partial response.

Identify your
ABECMA-eligible patients

Find a certified
treatment center near you